Good to see regrose posting. I've been thinking that we can produce more T cells specifically aimed at specific cancers than anyone else. When are we going to know the killing effect they are going to have on the cancer cells. Medical people I've talked to seem to be quite sure they will not be effective without something to alter the defenses the cancer cells have. How far have we come in knowing what is needed to make our indications strong enough to kill cancer cells. I have also heard that the thinking of some surgeons is that viruses may be caused by the cancer cells themselves and not the virus causing the cancer. Any other thoughts on this is appreciated. Hate to ask this as trials are on going, but I would of thought we would of had more data by now, and I know some of you are more aware of other trial results in this field.
Company says last year was a good year. I wonder what constitutes a bad year.......oh, wait, I think I see one shaping up.
Not funny, his handling of this company's financials has been dismal.
Also breaking a record for drawing a salary for the longest consecutive years without producing a dime in profit.
Come on man, he never gives factual information, he just throws names out there and timelines that are not even close. I haven't missed one in six years and they are dismal. Just a contract with revenue will say it all.
Yeah, but they weren't here six years ago like us. Don't you remember how we used to talk crazy numbers and get all worked up when AT spouted his lies at every CC. Don't you remember the big party when he said our baby is born indicating we were going to sell thousands of ShowX's. We thought we were making money and the mood was great. It's their turn, give thea break.
Threaten to drive the pps back to pennies like they are doing. Don't mess with Blackrock and their ilk. Dr. Kim jumped into the shark tank with the shelf offering and the RS and the rest is RS history. Roche walked on cancer indication and that was a huge blow. I wonder now if Dr. Kim is a decent negotiator at all. I would of expected him to try to keep Roche in the cancer game with a deal on one of our other indications. Makes me think Dr. Kim is not as good as we would like to think in that category.
Can't you see that that's the problem, no news. No news for months, no partnerships as was indicated last year. You nailed it, no news. Congratulate yourself, great analysis.
We need $100M for 3100 early next year. Where are they going to get it? Can't use all our current cash and fund ops without dilution. That is the crux of what is going on. Partnership is crucial. Failure to garner one last year and nothing happening so far is more than troublesome. Issuing shares at $7 or less is going to be expensive for longs. They might just offer a large discount for big buyers or do another RS. It is the uncertainty Dr. Kim has created that is killing the pps and investor confidence. If the pps continues to the $6 or $5 range we will not secure a good deal from any partner. Negotiating from a position of strength is what it is all about in this business. We have lost that position over the past ten months. Gonna be tough going forward.
Why not, they are partnering with a well run company who is well situated with products on the market. INCY was a jewel of mine and sold it for INO. Management there was stellar and partnerships were quality. Didn't lose one. Good relationship with all partners and financially rewarding. Solid company to partner with. Experiencing that I wonder why there is no real explanation for Roche leaving 5150?